$20.830
+0.233 (+1.12%)Zum Schluss
PRCT-News
PRCT-Events
Wood Company Sees FY26 Adjusted EBITDA Loss of $30M to $35M
Sees FY26 adjusted EBITDA loss $30M-$35M. Wood continued, "We also reached several important strategic milestones during the quarter, including completing enrollment in our WATER IV prostate cancer study and receiving a strengthened recommendation for Aquablation therapy in the updated American Urological Association guidelines. As we enter the second half of the year, we remain focused on execution and confident in our long-term opportunity to advance the standard of care in prostate disease."
WTI Crude Oil Rises Above $108 for Third Consecutive Day
Energy was once again the best-performing sector on Wednesday amid the ongoing Middle East tensions, with reports that President Trump is planning to maintain the naval blockade on Iran boosting WTI crude oil for the third consecutive day above $108 per barrel. Geopolitically driven risk-off bias was compounded by a Fed decision that featured multiple FOMC members dissenting with a majority not to include an easing bias in the statement, sending Treasuries sharply lower. The 10-year note yield jumped above 4.4% and the 30-year yield briefly touched 5% for the first time in months. Following the decision, Fed funds futures are once again pricing in a slight possibility of a rate hike by the end of 2026 at over 10%, and the slight possibility of a 25 basis point easing before year-end priced in pre-decision has now been erased.For the second day in a row however, earnings from the tech sector are helping to restore more constructive sentiment. Four Mag-7 companies reported results afterhours; Alphabet is the best performer with a 7% after-hours jump in stock price to record highs above $370 per share despite raising its FY26 CapEx view to $180B-$190B from $175B-$185B. Amazon's post-earnings price action saw a slight decline, but the stock flipped back into positive territory as CEO Jassy expressed confidence in the ROI of the company's accelerated CapEx and also touted the rapid growth of the company's chips business. Microsoft shares initially jumped to $445 on Q3 earnings beat but paired those gains to trade little changed as the company's Q4 revenue outlook midpoint came in shy of consensus. Meta fared the worst out of the mega-caps, falling over 6% with investors remaining skeptical that the company's investments may not pay off given that its AI initiatives are relatively earlier-stage. Outside the Mag-7, quarterly results from semiconductors remain impressive as Qualcommbeat estimates, with a surge of afterhours buying also driven by comments that the company would begin shipping data center chips to a large hyperscaler within a year.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Viavi Solutionsup 22.7%Impinjup 16.6%TTM Technologiesup 16.6%Qualcommup 13.3%FormFactorup 12.9%PROCEPT BioRoboticsup 12.4%Carvanaup 8.7%FMC Corporationup 7.4%Alphabetup 6.5%O'Reilly Automotiveup 4.2%Chipotleup 3.9%Amazonup 3.1%Cheesecake Factoryup 2.4%DOWN AFTER EARNINGS -Teladocdown 10.9%KLA Corp.down 7.6%Acadia Healthcaredown 6.6%Metadown 6.5%Waystardown 6.1%Equinixdown 5.7%Tenable Holdingsdown 5.7%Forddown 1.4%Matteldown 0.5%Microsoftdown 0.1%
Company Expects 39% to 48% U.S. Procedure Growth in 2026
The company continues to expect full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period. The company continues to expect full year 2026 gross margin to be approximately 65%. The company continues to expect full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million.
Company Reports Q1 Revenue of $83.1M, Exceeding Expectations
Reports Q1 revenue $83.1M, consensus $80.3M. The Company "recently received FDA clearance of its second-generation FirstAssist AI(TM) software, an advancement in personalized, image-guided planning for Aquablation therapy. This milestone further strengthens the capabilities of the HYDROS robotic system, the Company's next-generation AI-powered platform. The enhanced software enables more precise identification of prostate anatomy and more complete treatment planning to help surgeons plan with greater confidence and consistency." "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing. Aquablation(R) users completed approximately 12,200 U.S. procedures in the first quarter of 2026. Handpiece sales were about 95% of procedures, reflecting normalizing field inventory levels. While our recent commercial realignment created some near-term disruption, the team is adapting quickly, and we expect the benefits to build through the year, driving sustained growth and improved profitability."
Procept BioRobotics Expands Internationally with HYDROS Robotic System
Procept BioRobotics announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia. "Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects," said Larry Wood, President & CEO, PROCEPT BioRobotics. "The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.









